Table 1 Clinical and demographic characteristics of the study cohort (n = 63)

From: Cutaneous nerve fiber pathology and function in Parkinson’s disease and atypical parkinsonism – a cohort study

 

PD (n = 20)

MSA (n = 12)

4R (n = 11)

HC (n = 20)

p

  

[MSA-P, n = 8; MSA-C, n = 4]

[PSP-RS, n = 7; CBD, n = 4]

  

Age at examination (y), median (IQR)

63.2 (14.2)

59.3 (12.7)

68.6 (10.5)

62.9 (6.3)

0.084

Sex (M/F)

7/13

3/9

4/7

7/13

0.95

Smoking (n), (% yes)

1 (0.050)

1 (0.083)

0 (0)

1 (0.050)

1.0

Ethnicity (White/Asian/Hispanic/North African)

17/2/1/0

12/0/0/0

9/1/0/1

20/0/0/0

0.22

Disease characteristics

 Onset age (y), median (IQR)

57.6 (13.6)

52.0 (11.1)

65.0 (12.5)

.

0.041

 Disease duration (y), median (IQR)

6.5 (4.9)

5.8 (1.6)

4.4 (3.1)

.

0.046

 L-dopa duration (y), median (IQR)

4.1 (4.4)

2.7 (4.3)

0.2 (2.6)

.

0.024

 LEDD (mg), median (IQR)

593 (549)

688 (1201)

200 (600)

.

0.049

 mHY (stage), median (IQR)

2.0 (0)

4.0 (2.0)

4.0 (2.0)

.

<0.001

 MDS-UPDRS part III (p), median (IQR)

23 (15)

.

.

.

.

 UMSARS part II (p), median (IQR)

.

29.5 (18)

.

.

.

 UMSARS part IV (p), median (IQR)

.

3 (1)

.

.

.

 PSP-CDS (p), median (IQR)

.

.

11 (9)

.

.

 SCOPA-AUT (p), median (IQR)

10.5 (10)

31.5 (20)

13 (20)

5.5 (7)

<0.001

 Max. systolic BP fall (mmHg), median (IQR)

8.5 (7)

16 (18)

5 (20)

9.5 (15)

0.34

 Max. diastolic BP fall (mmHg), median (IQR)

0.0 (8)

8.5 (10)

1.0 (12)

0.5 (11)

0.033

 UENS (p), median (IQR)

5.0 (5)

3.0 (3)

3.0 (4)

2.0 (2)

0.004

 p-neurofilament light (pg/mL), median (IQR)

14.4 (8.9)

32.4 (23.7)

28 (29.1)

9.8 (6.2)

<0.001

  1. Overview of the study cohort. Data are presented with non-parametric descriptive statistics. Group comparisons performed with Fisher’s exact test and Kruskal–Wallis H-test.
  2. PD Parkinson’s disease, MSA-P/C multiple system atrophy with predominant parkinsonism/cerebellar features, 4R four-repeat tauopathy, CBD corticobasal degeneration, PSP-RS probable progressive supranuclear palsy–Richardson syndrome, HC healthy control, IQR interquartile range, LEDD L-dopa equivalent daily dose, mHY modified Hoehn & Yahr, MDS-UPDRS Movement Disorders Society Unified Parkinson’s Disease Rating Scale, UMSARS Unified Multiple System Atrophy Rating Scale, PSP-CDS Progressive Supranuclear Palsy Clinical Deficits Scale, SCOPA-AUT Scales for Outcomes in Parkinson’s Disease-Autonomic Dysfunction, BP blood pressure, UENS Utah Early Neuropathy Scale, p plasma.
  3. Bold indicates p < 0.05.
Back to article page